Voting Rights and Company Capital | 13.11.24

L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the French Financial Markets Authority (Autorité des Marchés Financiers). in accordance with the articles

PARIS, November 13, 2024 (GLOBE NEWSWIRE) —

Paris, France, 13 November 2024
Market: Euronext Paris / Nasdaq
Euronext Division: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

History	Number of Shares Available	Total number of voting rights
		Total voting rights, theoretical¹	Total voting rights, applicable²
31 October 2024	47,426,851	49,201,086	49,178,968

***

About NANOBIOTICS

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches that are revolutionizing treatment outcomes for millions of patients; It is supported by people determined to make a difference for humanity. The company’s philosophy is based on the concept of pushing the boundaries of what is known to expand the possibilities for human life.

Founded in 2003, Nanobiotix is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The company has subsidiaries in Cambridge, Massachusetts (United States), among other locations.

Nanobiotix, 1) oncology; 2) bioavailability and biodistribution; and 3) central nervous system disorders.

For more information about Nanobiotix, visit us: www.nanobiotix.com or follow us LinkedIn And excitement.

Contacts

nanobiotics
Communications Department Brandon Owens Vice President, Communications +1 (617) 852-4835 [email protected]	Investor Relations Department Craig West Senior Vice President, Investor Relations +1 (617) 583-0211 [email protected]
Media Relations
FR – Ulysse Contact Laurent Wormser + 33 (0)6 13 12 04 04 [email protected]	Global – Life Science Consultants Kevin Gardner +1 (617) 283-2856 [email protected]

¹
The calculation of threshold crossings is based on the total number of theoretical (or “gross”) voting rights. This issue is based on Article 223-11 of the AMF General Regulation. It is calculated on the basis of all shares with voting rights in accordance with the article. Attached, including those whose voting rights have been suspended.

²
The total number of voting rights (or “net”) that can be exercised at the general assembly meeting is calculated without taking into account shares whose voting rights are suspended as shares held by the Company in the treasury. Properly informing the public in accordance with the AMF’s recommendation dated 17 July 2007.

2024-11-13 — NBTX — Voting Rights and Share Capital — FINAL

Related Posts